A comparative study between oral itraconazole and terbinafine in tinea infection

A comparative study of effect of oral itraconazole and terbinafine in tinea infection with species identification of dermatophtyes isolated from superficial fungal infections at tertiary care centre - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058844

Enrollment

Registered

2023-10-18

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: comparative study between oral itraconazole and terbinafine in tinea infection: oral itracoanzole 200mg will be given once a day for 6 weeks Intervention2: comparative study between ora

Eligibility

Inclusion criteria

Inclusion criteria: -all KOH positive tinea cases of age between 18 and 65 years -body surface area involvement more than 5% -patient giving written informed consent for study

Exclusion criteria

Exclusion criteria: -pregnant and lactating women -patient with preexisting renal, hepatic and cardiac disease -patient with onychomycosis

Design outcomes

Primary

Measure	Time frame
By assessing dercrease in erythema, scaling, vesiculation, fissuring, maceration, exudationTimepoint: baseline, 3 weeks, 6 weeks and 12 weeks	—

Secondary

Measure	Time frame
to know about relapseTimepoint: at 3 months follow up	—

Countries

India

Contacts

Public ContactAnkita Narola

Mahatma Gandhi Hospital

dr.sankalp.avasthi@gmail.com9411865323

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026